To the Editor: Dr Stewart and colleagues1 review and discuss recommendations for examining
women at risk for health complications during the use of hormonal contraceptives.
The list of eligibility for use of progestin-only contraceptives, adapted
from the World Health Organization (WHO) as well as the authors' discussion
of such contraceptives, fails to consider the presence of a mood disorder
as a need for caution or special monitoring. However, progestin-only implants
have been associated with an increased incidence of depressive symptoms in
postpartum women.2